Glythera Limited is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glytheras portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr Jon Roffey to the companys Scientific Advisory Board (SAB).
sterna biologicals GmbH & Co. KG announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer.
Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.
Targovax ASA (OSE: TRVX) announces that Michael Bogenstaetter has been appointed as the Company’s Chief Business Officer (CBO). He will take up this role in January 2018.
Stevenage Bioscience Catalyst (SBC) has announced that Dr. Sally Ann Forsyth is set to join the company as CEO in March 2018.
Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.
Symcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
Belgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
Swedish specialty pharmaceutical company Pharmalink AB Stockholm has Fredrik Johansson as new Chief Financial Officer.
Gene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.